
아르기닌 대사 조절을 통해 면역 억제적 M2형 종양 관련 대식세포를 면역 활성화 M1형으로 재프로그래밍하여 HER2 양성 유방암의 면역 반응을 증진시킬 수 있다.


coremsg

HER2+ breast tumors have abundant immune-suppressive cells, including M2-type tumor associated macrophages (TAMs). While TAMs consist of the immune-stimulatory M1-type and immune-suppressive M2-type, M1/M2-TAM ratio is reduced in immune-suppressive tumors, contributing to their immunotherapy refractoriness. M1 vs. M2-TAM formation depends on differential arginine metabolism, where M1-TAMs convert arginine to nitric oxide (NO) and M2- TAMs convert arginine to polyamines (PAs). We hypothesize that such distinct arginine metabolism in M1- vs M2-TAMs is attributed to different availability of BH4 (NO synthase cofactor) and that its replenishment would reprogram M2-TAMs to M1-TAMs. Recently, we reported that sepiapterin (SEP), the endogenous BH4 precursor, elevates the expression of M1- TAM markers within HER2+ tumors. Here, we show that SEP restores BH4 levels in M2-TAMs, which then redirects arginine metabolism to NO synthesis and converts M2-TAMs to M1-TAMs. The reprogrammed TAMs exhibit full-fledged capabilities of antigen presentation and induction of effector T cells to trigger immunogenic cell death of HER2+ cancer cells. This study substantiates the utility of SEP in metabolic shift of HER2+ breast tumor microenvironment as a novel immunotherapeutic strategy.

Reprogramming of breast tumor-associated macrophages with modulation of arginine metabolism

her2-양성-유방암에서-아르기닌-대사-조절을-통한-종양-관련-대식세포의-재프로그래밍


HER2 양성 유방암에서 아르기닌 대사 조절을 통한 종양 관련 대식세포의 재프로그래밍
